Vertex Pharmaceuticals ( VRTX) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs, and ...
Shares of Vertex Pharmaceuticals Inc. VRTX rallied 2.53% to $482.28 Tuesday, on what proved to be an all-around great trading ...
Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 20 years ago, it would be worth $4,232.95 today based on a ...
AbbVie, Vertex Pharmaceuticals, and Thermo Fisher Scientific are the three Biotech stocks to watch today, according to ...
The S&P 500 index trades at a forward price/earnings ratio of 21.9. The U.S. large-cap benchmark stock index is weighted by market capitalization. The index's current forward P/E valuation is 18% ...
Opinion
17hOpinion
Zacks.com on MSNEarnings Season Scorecard and Analyst Reports for Meta Platforms, Mastercard & AdobeToday's Research Daily features the Q4 earnings season scorecard and updated analyst reports on 16 major stocks, including Meta Platforms (META), Mastercard (MA) and Adobe (ADBE), as well as two micro ...
AbbVie, Eli Lilly and Company, Vertex Pharmaceuticals, Thermo Fisher Scientific, and Johnson & Johnson are the five ...
UnitedHealth Group, AbbVie, Eli Lilly and Company, Vertex Pharmaceuticals, and Walmart are the five Medical stocks to watch today, according to MarketBeat’s stock screener tool. Medical stocks refer ...
20h
Zacks.com on MSNGilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 ReleaseGilead Sciences (GILD) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook ...
We recently compiled a list of the The 10 Worst-Performing Stocks on Monday. In this article, we are going to take a look at where Moderna Inc. (NASDAQ:MRNA) stands against the other stocks. Ten ...
BofA analyst Tazeen Ahmad raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $540 from $522 and keeps a Buy rating on the ...
Comprehensive Financial Consultants Institutional Inc. grew its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 4.0 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results